GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

IMDX · Mar 31, 2024

Insight Molecular Diagnostics Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-24-019842General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

13.64% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-2176.14% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-40.74% · CORE · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

-55.68% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-5265.34% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1232.39% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

237.50% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/5 normalizedLevel 3Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/5 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20245/8 normalizedLevel 3Mar 31, 20255/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
18.70%
Current
13.64%
Delta
-5.06%
Cash Generation Decreased
Previous
-1551.90%
Current
-2176.14%
Delta
-624.24%
Growth Decreased
Previous
56.89%
Current
-40.74%
Delta
-97.63%
Margin Decreased
Previous
27.48%
Current
-55.68%
Delta
-83.16%
Profitability Decreased
Previous
-1672.39%
Current
-5265.34%
Delta
-3592.95%
R And D Intensity Increased
Previous
618.36%
Current
1232.39%
Delta
614.02%
Sbc Intensity Increased
Previous
183.63%
Current
237.50%
Delta
53.87%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · IMDX Fundamental State →Transitioned To · IMDX Fundamental State →Transitioned To · IMDX CAPEX_INTENSITY_DECREASED →Transitioned To · IMDX CASH_GENERATION_DECREASED →Transitioned To · IMDX GROWTH_DECREASED →Transitioned To · IMDX MARGIN_DECREASED →Transitioned To · IMDX PROFITABILITY_DECREASED →Transitioned To · IMDX R_AND_D_INTENSITY_INCREASED →Transitioned To · IMDX SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.